دواعي استعمال بوليفي 140 مجم فيال وريدي

Polatuzumab vedotin 140 mg lyophilised powder vial for intravenous infusion (Roche), a CD79b-directed antibody-drug conjugate for diffuse large B-cell lymphoma.

• With rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) for adults with previously untreated DLBCL NOS or HGBL with IPI score >= 2الفئة: AdultsDailyMed (US NLM)
• With bendamustine and a rituximab product for adults with relapsed or refractory DLBCL NOS after at least two prior therapiesالفئة: AdultsDailyMed (US NLM)

• None listed in the US label.نشرة دولية لنفس المنتج · DailyMed (US NLM)

• Peripheral neuropathy, including severe cases; cumulative and may exacerbate pre-existing neuropathy.نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Infusion-related reactions, including delayed reactions up to 24 hours.نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Serious or severe myelosuppression (neutropenia, febrile neutropenia, thrombocytopenia, anaemia).نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Fatal or serious infections including opportunistic infections (sepsis, pneumonia, herpesvirus, CMV).نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Progressive multifocal leukoencephalopathy has been reported.نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Tumour lysis syndrome, especially with high tumour burden.نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Hepatotoxicity (transaminase/bilirubin elevations).نشرة دولية لنفس المنتج · DailyMed (US NLM)
• Can cause embryo-fetal harm.نشرة دولية لنفس المنتج · DailyMed (US NLM)

• Advise women not to breastfeed.نشرة دولية لنفس المنتج · DailyMed (US NLM)

• Monitor for peripheral neuropathy, infusion reactions, complete blood counts, signs of infection, neurological changes (PML), tumour lysis, liver enzymes and bilirubin.نشرة دولية لنفس المنتج · DailyMed (US NLM)

• Antibody-drug conjugate targeting CD79b on B cells; releases the microtubule inhibitor MMAE inside the cell.